Singapore, 6 October 2021 – A team of clinicians and scientists from the National Cancer Centre Singapore (NCCS), Singapore General Hospital (SGH) and A*STAR’s Genome Institute of Singapore (GIS) has identified a novel method to treat triple-negative breast cancer (TNBC). They discovered that cancer cells switch between different cell states and are able to change from being less aggressive (‘epithelial’) to being more aggressive (‘mesenchymal’), and vice versa. By converting highly aggressive cancer cells to become less aggressive, tumours are primed to respond better to chemotherapy, which works to eliminate cancer cells. This discovery has led to the launch of a three-year long human clinical trial, BEXMET (Bexarotene-induced Mesenchymal-Epithelial Transition), to investigate this unconventional approach to treating TNBC.
Hikma`s Generic Everolimus Bexarotene Receives Approval In US
Enforcement Report - Week of August 28, 2019
Amneal Pharms` Generic Bexarotene Receives Approval in US
Upsher-Smith Labs's Generic Bexarotene Receives Approval In US
Amerigen Pharma Ltd's Generic Miglustat Receives FDA Approval
The team from the UK, Sweden and the Netherlands have shown in preclinical studies that a drug called bexarotene seems to work as a 'neurostatin', preventing the degeneration of nerve cells in a model of Alzheimer's disease (AD) by preventing the production of neurotoxic beta-amyloid aggregates.
One defense from small drugmakers that have bought older products and hiked their prices: Their drugs are used by a small number of patients, so the higher cost isn't much of a hit to the healthcare system. The slow-but-steady price increases on blockbuster meds are a bigger problem, they say.
Retail prices of 19 brand-name prescription drugs for dermatologic conditions ranging from acne to cancer increased fivefold on average between 2009 and 2015, according to a study that adds new fuel to the burgeoning debate over the cost of medicines.